InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Bausch + Lomb is taking bold action to address a unique, yet growing, issue: contact lens and packaging waste.

InflammX Therapeutics, Inc. has entered into an option agreement granting Bausch + Lomb the right to acquire the company. InflammX’s pipeline includes an orally dosed therapeutic candidate targeting ...